T
LPCN icon

Tidemark’s Lipocine LPCN Stock Holding History

Tidemark’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$471 Hold
59
– – ﹤0.01% 767
2025
Q4 		$474 Hold
59
– – ﹤0.01% 626
2025
Q3 		$168 Hold
59
– – ﹤0.01% 670
2025
Q2 		$186 Hold
59
– – ﹤0.01% 692
2025
Q1 		$188 Buy
+59
New +$228 ﹤0.01% 693
2024
Q4 		– Sell
-59
Closed -$265 – 662
2024
Q3 		$265 Hold
59
– – ﹤0.01% 610
2024
Q2 		$486 Hold
59
– – ﹤0.01% 591
2024
Q1 		$307 Hold
59
– – ﹤0.01% 675
2023
Q4 		$165 Buy
+59
New +$156 ﹤0.01% 677

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Tidemark's LPCN Position: Q1 2026 in Review

Tidemark held its Lipocine (LPCN) position steady in Q1 2026 at 59 shares worth $471. The position accounts for ﹤0.01% of the portfolio, ranked #767.

Tidemark first reported a position in LPCN in Q4 2023 and has held it in 9 quarters since. The position peaked at $486 in Q2 2024. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Tidemark held 59 shares of Lipocine worth $471 as of Q1 2026.
  • Tidemark left its Lipocine share count unchanged in Q1 2026.
  • Lipocine made up ﹤0.01% of Tidemark's portfolio in Q1 2026, its #767 holding.
  • Tidemark first reported a position in Lipocine in Q4 2023 and has held it in 9 quarters since.
  • Tidemark's Lipocine position peaked at $486 in Q2 2024.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Tidemark's 13F filing for Q1 2026, filed 7 May 2026.